XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic orUnresectable Leiomyosarcoma, Bone Sarcoma, orTranslocation-Associated Soft Tissue Sarcoma
Trial ID: NCT06571734
Phase: Phase 2
Status: Recruiting
Last Update Posted: May 2026
Eligibility: Adults aged 18 and older with metastatic or unresectable leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma, including synovial sarcoma, who have received at least two prior lines of therapy and no more than two prior tyrosine kinase inhibitors, and have measurable disease.
Overview: This Phase 2 trial, sponsored by Northwestern University and coordinated by Seth Pollack, MD, investigates zanzalintinib (XL092), a next-generation oral tyrosine kinase inhibitor in the same drug family as pazopanib (Votrient). The translocation-associated sarcoma arm of this trial was specifically designed with synovial sarcoma in mind. XL092 is taken once daily in 14-day cycles and is believed to be better tolerated and potentially more effective than similar drugs currently available. The leiomyosarcoma cohort has already completed accrual with encouraging early signals, and enrollment is now open for the synovial sarcoma cohort.
Preliminary Effectiveness: The leiomyosarcoma cohort has shown encouraging early results and the drug appears well tolerated. Efficacy data in synovial sarcoma is still being collected and it is too early to draw conclusions, but researchers are hopeful.

Study Contact: Northwestern University

Treatment Centers:

  • Northwestern University, Chicago, IL

More Information: trialx.com/clinical-trials/listings/300292 | cancer.gov trial
listing